{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:08:36Z","timestamp":1779170916033,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) involves progressive dopaminergic neuron loss in the substantia nigra (SN). Aldehyde dehydrogenase 1A1 (ALDH1A1), the rate-limiting enzyme in retinoic acid biosynthesis, is enriched in vulnerable dopaminergic neuron subpopulations and is consistently downregulated in PD. However, the relationship between ALDH1A1 expression and broader dopaminergic pathway gene co-expression has not been systematically characterized across multiple independent datasets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Gene expression correlations were analyzed across seven independent human SN microarray datasets (\n                      <jats:italic>n<\/jats:italic>\n                      = 156; 70 controls, 86 PD) from the Gene Expression Omnibus. Simple arithmetic means across datasets are reported as the primary summary statistic; random-effects meta-analysis with DerSimonian-Laird estimation was applied to Fisher\u2019s z-transformed correlation coefficients to generate pooled estimates with heterogeneity statistics. Marker gene-based enrichment scoring using published cell type markers from single-nucleus RNA-seq profiling of human substantia nigra\u2014with all target genes excluded from signatures\u2014was performed across six analyzable datasets. Selectivity of ALDH1A1 correlation attenuation was assessed using permutation testing (\n                      <jats:italic>n<\/jats:italic>\n                      = 5,000) as the primary statistical test, with parametric tests reported as supplementary.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In controls, ALDH1A1 showed strong co-expression with dopaminergic genes (mean r = 0.92\u20130.93 for TH, DDC, and SLC18A2). In PD, these correlations were attenuated (mean \u0394r = \u22120.336 for ALDH1A1-dopamine pairs). Dopamine-dopamine correlations showed less attenuation (mean \u0394r = \u22120.143). Marker gene-based enrichment scoring confirmed significant depletion of ALDH1A1-positive vulnerable dopaminergic neurons in 4 of 6 datasets. After adjusting for estimated cell type enrichment, the selectivity of ALDH1A1 attenuation was preserved (adjusted selectivity: \u22120.210, increased from raw selectivity of \u22120.190; raw permutation\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0052).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ALDH1A1 co-expression with dopaminergic pathway genes is attenuated in PD substantia nigra across all seven datasets examined. This attenuation is selective for ALDH1A1-containing pairs, and this selectivity persists after adjusting for cell type enrichment changes. While correlational, these findings are consistent with a role for retinoic acid pathway disruption in PD pathophysiology and warrant mechanistic investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2026.1806505","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:39:54Z","timestamp":1779169194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ALDH1A1-dopaminergic gene co-expression in human substantia nigra: meta-analysis of disease-associated correlation changes across seven independent Parkinson\u2019s disease datasets"],"prefix":"10.3389","volume":"18","author":[{"given":"Drake H.","family":"Harbert","sequence":"first","affiliation":[{"name":"Inner Architecture LLC","place":["Canton, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.brainres.2011.06.051","article-title":"Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system.","volume":"1408","author":"Anderson","year":"2011","journal-title":"Brain Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape.","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2014.226","article-title":"The ongoing pursuit of neuroprotective therapies in Parkinson disease.","volume":"11","author":"Athauda","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1002\/9780470743386","volume-title":"Introduction to Meta-Analysis.","author":"Borenstein","year":"2009"},{"key":"B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson\u2019s disease.","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1172\/JCI90609","article-title":"CNS inflammation and neurodegeneration.","volume":"127","author":"Chitnis","year":"2017","journal-title":"J. Clin. Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"B8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnagi.2015.00020","article-title":"Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson\u2019s disease.","volume":"7","author":"Esteves","year":"2015","journal-title":"Front. Aging Neurosci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.nbd.2006.05.015","article-title":"ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson\u2019s disease and in the ventral tegmental area in schizophrenia.","volume":"23","author":"Galter","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.brainres.2011.10.026","article-title":"Retinoic acid signaling in neuronal development and degeneration.","volume":"1441","author":"Goodman","year":"2012","journal-title":"Brain Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"10744","DOI":"10.1073\/pnas.0401319101","article-title":"Gene expression profiling of Parkinsonian substantia nigra pars compacta.","volume":"101","author":"Gr\u00fcnblatt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.4103\/1673-5374.380878","article-title":"Single-neuron neurodegeneration as a degenerative model for Parkinson\u2019s disease.","volume":"19","author":"Huenchuguala","year":"2023","journal-title":"Neural Regen. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"13992","DOI":"10.1523\/JNEUROSCI.1942-07.2007","article-title":"Retinoic acid counteracts motor neuron apoptosis in the degenerating midbrain of the mouse model of Parkinson\u2019s disease.","volume":"27","author":"Jacobs","year":"2007","journal-title":"J. Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1523\/JNEUROSCI.0809-08.2009","article-title":"Pitx3 potentiates Nurr1 in dopamine neuron terminal differentiation through direct interaction with Nurr1.","volume":"29","author":"Jacobs","year":"2009","journal-title":"J. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/mds.26354","article-title":"Disease-modifying strategies for Parkinson\u2019s disease.","volume":"30","author":"Kalia","year":"2015","journal-title":"Mov. Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/s41593-022-01061-1","article-title":"Single-cell genomic profiling of human dopamine neurons identifies a population that selectively degenerates in Parkinson\u2019s disease.","volume":"25","author":"Kamath","year":"2022","journal-title":"Nat. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.cell.2016.09.027","article-title":"Molecular diversity of midbrain development in mouse, human, and stem cells.","volume":"167","author":"La Manno","year":"2016","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1172\/JCI72176","article-title":"Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation.","volume":"124","author":"Liu","year":"2014","journal-title":"J. Clin. Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrn2212","article-title":"Retinoic acid in the development, regeneration and maintenance of the nervous system.","volume":"8","author":"Maden","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1196\/annals.1344.031","article-title":"Gene expression profiling of sporadic Parkinson\u2019s disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.","volume":"1053","author":"Mandel","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"7772","DOI":"10.1073\/pnas.91.16.7772","article-title":"High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system.","volume":"91","author":"McCaffery","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry.","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease.","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1038\/s41598-017-05598-1","article-title":"Aldehyde dehydrogenase 1-positive nigrostriatal dopaminergic fibers exhibit distinct projection pattern and dopamine release dynamics at mouse dorsal striatum.","volume":"7","author":"Sgobio","year":"2017","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"B28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1189\/jlb.3MR0416-204R","article-title":"Danger-associated molecular patterns in Alzheimer\u2019s disease.","volume":"101","author":"Venegas","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1006\/excr.1999.4691","article-title":"Fate of mesencephalic AHD2-expressing dopamine progenitor cells in NURR1 mutant mice.","volume":"253","author":"Wall\u00e9n","year":"1999","journal-title":"Exp. Cell Res."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1806505\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:39:59Z","timestamp":1779169199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2026.1806505\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":29,"alternative-id":["10.3389\/fnagi.2026.1806505"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2026.1806505","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1806505"}}